Uniform timing definitions, an explicit hierarchy separating direct evidence from extrapolation, and tumor-specific rather than universal rules for checkpoint inhibitor re-exposure are proposed for checkpoint inhibitor re-exposure.
F. Petrelli, L. Dottorini, A. Ghidini et al.· Current Oncology· 0 citations
Time-of-day of treatment, seasonality, latitude-related sunlight exposure, vitamin D status, and circadian rhythm integrity are potentially relevant determinants of systemic therapy outcomes.
A. Ghidini, L. Roncari, R. Bukovec et al.· Critical reviews in oncology...· 0 citations
This review synthesizes how nerves and brain activity directly influence tumour growth across multiple diseases—including gliomas, small cell lung cancer, breast cancer, pancreatic cancer, and prostate cancer—and how these neural signals converge with metabolic and drug-resistance pathways that limit the efficacy of co...
F. Petrelli, A. Callea, A. Ghidini et al.· Medical Oncology· 0 citations
Within RCC, bladder cancer, and NSCLC, next-generation PD-(L)1 combinations are reshaping treatment across all disease stages, and the magnitude of benefit, the relevant biomarkers, and the toxicity trade-offs differ substantially by tumor type and by setting.
F. Petrelli, Lara Colombo Zefinetti, A. D'Alessio et al.· Current Oncology Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
